Inotek Pharmaceuticals

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Lexington, US
Size (employees)
17 (est)-5%
Inotek Pharmaceuticals was founded in 1996 and is headquartered in Lexington, US

Key People at Inotek Pharmaceuticals

Paul G. Howes

Paul G. Howes

President and CEO

Inotek Pharmaceuticals Office Locations

Inotek Pharmaceuticals has an office in Lexington
Lexington, US (HQ)
33 Hayden Avenue

Inotek Pharmaceuticals Data and Metrics

Inotek Pharmaceuticals Financial Metrics


Net income (FY, 2016)

(42.9 m)

EBIT (FY, 2016)

(41.9 m)

Market capitalization (23-Jun-2017)

48.6 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

29.8 m
Inotek Pharmaceuticals's current market capitalization is $48.6 m.
USDFY, 2015FY, 2016

R&D expense

(12.6 m)(32 m)

General and administrative expense

(7.8 m)(9.9 m)

Operating expense total

(20.4 m)(41.9 m)


(20.4 m)(41.9 m)

Interest expense

(1.2 m)(1.4 m)

Interest income

89 k443 k

Net Income

(68 m)(42.9 m)
USDFY, 2015FY, 2016


80 m29.8 m


1.1 m1.9 m

Current Assets

112.4 m128.3 m


812 k1.1 m

Total Assets

113.3 m129.6 m

Accounts Payable

1.6 m1.6 m

Current Liabilities

4.1 m7.2 m

Additional Paid-in Capital

304.6 m311.8 m

Retained Earnings

(196 m)(238.9 m)

Total Equity

108.8 m73.2 m

Financial Leverage

1 x1.8 x
USDFY, 2015FY, 2016

Net Income

(68 m)(42.9 m)

Depreciation and Amortization

45 k169 k

Accounts Payable

487 k(41 k)

Cash From Operating Activities

(17.4 m)(37.3 m)

Purchases of PP&E

(412 k)(487 k)

Cash From Investing Activities

(31.7 m)(66.1 m)

Short-term Borrowings

(5.8 m)(5.8 m)

Cash From Financing Activities

125.5 m53.1 m

Interest Paid

89 k89 k
Y, 2016

Financial Leverage

1.8 x

Inotek Pharmaceuticals Operating Metrics

FY, 2016

Patent Portfolios


Phase III Trials


Inotek Pharmaceuticals Market Value History

Inotek Pharmaceuticals Company Life and Culture

You may also be interested in